Literature DB >> 26367026

Lung disease and ulcerative colitis--mesalazine-induced bronchiolitis obliterans with organizing pneumonia or pulmonary manifestation of inflammatory bowel disease?

A Moeser1, M W Pletz2, S Hagel1, C Kroegel3, A Stallmach4.   

Abstract

Ulcerative colitis can be associated with numerous extraintestinal organ manifestations. Pulmonary disease in inflammatory bowel disease (IBD) is supposed to be a rare entity and has to be distinguished from infectious complications and side-effects of medications used in the treatment of IBD. We present the case of a 20-year-old male patient with ulcerative colitis and a 4-week history of respiratory symptoms, malaise, fever and respiratory insufficiency under a medication with mesalazine. Computed tomography showed bilateral subpleural consolidations, bronchoscopy revealed signs of acute bronchitis. The diagnostic work-up ruled out an infectious cause. Under the tentative diagnosis of a mesalazine-induced bronchiolitis obliterans with organizing pneumonia (BOOP) the medication with mesalazine was withdrawn and the patient received a corticosteroid trial. The symptoms quickly improved and prednisone was tapered and stopped after 6 months. Unexpectedly, lung function after complete resolution of respiratory symptoms revealed a residual obstructive ventilatory defect that might be due to an asymptomatic pulmonary manifestation of ulcerative colitis. A review of the literature shows that pulmonary manifestations in IBD as well as pulmonary toxicity of mesalazine might not be as rare as expected and should be included as differential diagnoses in the work-up of respiratory symptoms in patients with IBD. A pragmatic therapeutic approach is reasonable in critically ill patients as it is not always easy to distinguish both entities. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26367026     DOI: 10.1055/s-0041-103377

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  6 in total

Review 1.  [Aspects of pulmonary involvement in inflammatory bowel disease].

Authors:  A Moeser; M Lerche; H Wirtz; A Stallmach
Journal:  Internist (Berl)       Date:  2018-09       Impact factor: 0.743

2.  Combined treatment with sinomenine and acupuncture on collagen-induced arthritis through the NF-κB and MAPK signaling pathway.

Authors:  Minmin Xu; Shaofan Liu; Ruijie Wan; Yu Chen
Journal:  Oncol Lett       Date:  2018-03-30       Impact factor: 2.967

3.  Inflammatory bowel disease and risk of idiopathic pulmonary fibrosis: A protocol for systematic review and meta-analysis.

Authors:  Jiali Wang; Fushun Kou; Xiao Han; Lei Shi; Rui Shi; Zhibin Wang; Tangyou Mao; Junxiang Li
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

4.  Prevalence of Pulmonary Diseases in Association with Inflammatory Bowel Disease.

Authors:  Gayatri Pemmasani; Edward V Loftus; William J Tremaine
Journal:  Dig Dis Sci       Date:  2022-02-10       Impact factor: 3.487

5.  Pulmonary involvement in Crohn's disease.

Authors:  Rodolfo Augusto Bacelar de Athayde; Felipe Marques da Costa; Ellen Caroline Toledo do Nascimento; Roberta Karla Barbosa de Sales; Andre Nathan Costa
Journal:  J Bras Pneumol       Date:  2018 Nov-Dec       Impact factor: 2.624

6.  Mesalazine-related lung disease in a patient with ulcerative colitis: A case report.

Authors:  Po-Han Huang; Chia-Jung Kuo; Chang-Wei Lin; Yu-Ming Cheng; Han-Chung Hu; Chun-Yen Lin; Ming-Yao Su; Cheng-Tang Chiu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.